SCHEMBL3476809

SCHEMBL3476809

O=C(NCCCc1ccccc1)Nc1[nH]c2ccc(Br)cc2c1S(=O)(=O)N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
EPHX1 P07099 1/20 0.41
FKBP1A P62942 3/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
NAMPT P43490 2/20 0.40
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
CXCR2 P25025 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 1/20 0.38
CNR1 P21554 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3477801 0.95 ALDH1A1 (0.43) KDM4ENAMPTALDH1A1GAACXCR2
SCHEMBL3476757 0.89 NAMPT (0.52) NAMPTALDH1A1MEN1KMT2AGAA
SCHEMBL3478247 0.87 L3MBTL1 (0.41) KDM4EEPHX1NAMPTALDH1A1MEN1
SCHEMBL3476880 0.85 KDM4E (0.41) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL3477796 0.84 TSHR (0.49) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3477114 0.83 MAPT (0.51) KDM4ENAMPTALDH1A1MEN1KMT2A
SCHEMBL3477440 0.83 LMNA (0.43) ALDH1A1KMT2AGAASMN1; SMN2LMNA
SCHEMBL3477830 0.83 LMNA (0.41) KMT2AGAACXCR2LMNACNR1
SCHEMBL3476335 0.82 NAMPT (0.45) ROCK2NAMPTALDH1A1MEN1KMT2A
SCHEMBL3476271 0.82 NAMPT (0.57) ROCK2NAMPTALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US claimed
EP-1898927-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP claimed
WO-2007002481-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, RTF1, POLR1E KDM4E 1660/4885EPHX1 1273/4885FKBP1A 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.